A Double-blind, Placebo-controlled, Study Examining the Effect of Orally Administered QAW039 (450 mg QD) on FEV1 and ACQ in Non-atopic, Asthmatic Patients With a Baseline, Pre-bronchodilator FEV1 of 40-80% Predicted, Inadequately Controlled With Low Dose ICS Therapy
Phase of Trial: Phase II
Latest Information Update: 23 Mar 2017
At a glance
- Drugs Fevipiprant (Primary) ; Corticosteroids
- Indications Asthma
- Focus Therapeutic Use
- Sponsors Novartis
- 10 Mar 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 03 Nov 2014 Planned End Date changed from 1 Apr 2015 to 1 Aug 2015 as reported by ClinicalTrials.gov record.
- 03 Nov 2014 Planned primary completion date changed from 1 Apr 2015 to 1 Aug 2015 as reported by ClinicalTrials.gov record.